Publicaciones de Mariana Prestes

2018

  • Tratamiento farmacológico de la diabetes tipo 2: su costo está significativamente asociado con los niveles de HbA1c. Elgart JF, Silvestrini C, Prestes M, Gonzalez L, Rucci E, Gagliardino JJ. XXI Congreso Argentino de Diabetes, Sociedad Argentina de Diabetes (SAD). Revista de la SAD. 2018; 52:95-96.
  • Ingesta alimentaria en la población adulta de dos ciudades de la Provincia de Buenos Aires: su adecuación a las recomendaciones nutricionales. García S, Fantuzzi G, Angelini JM, Bourgeois M, Elgart JF, Etchegoyen G, Giampieri C, González L, Kronsbein P, Martínez C, Martínez J, Prestes M, Ré M, Ricart A, Ricart JP, Gagliardino JJ. Actualización en Nutrición. 2018 Jun; 19(2): 38-43. (ISSN 1667-8052).

2017

  • Relation between cost of drug treatment and body mass index in people with type 2 diabetes in Latin America. Elgart JF, Prestes M, Gonzalez L, Rucci E, Gagliardino JJ; QUALIDIAB Net study group. PLoS One. 2017 Dec 20;12(12):e0189755. doi: 10.1371/journal.pone.0189755.
  • Improving diabetes care at primary care level with a multistrategic approach: results of the DIAPREM programme. Prestes M, Gayarre MA, Elgart JF, Gonzalez L, Rucci E, Paganini JM, Gagliardino JJ; DIAPREM (DIAbetes Primary Care, Registry, Education and Management). Acta Diabetol. 2017 Jun 17. doi: 10.1007/s00592-017-1016-8.
  • Multistrategic approach to improve quality of care of people with diabetes at the primary care level: Study design and baseline data. Prestes M, Gayarre MA, Elgart JF, Gonzalez L, Rucci E, Gagliardino JJ; DIAPREM (DIAbetes Primary Care, Registry, Education and Management). Prim Care Diabetes. 2017 Apr;11(2):193-200.
  • Resultados de la Implementación de una estrategia combinada de Educación y Gestión de Pacientes en Centros de Atención Primaria de Argentina. Prestes M, Gayarre MA, Elgart JF, Rucci E, Paganini JM, Gagliardino JJ. ISPOR 6th Latin America Conference (Sao Pablo, Brasil). Value in Health, 2017; 20(9):A857–A858.

2016

  • Frequency of self-monitoring blood glucose and attainment of HbA1c target values. Elgart JF, González L, Prestes M, Rucci E, Gagliardino JJ. Acta Diabetologica. Feb; 53(1):57-62. doi: 10.1007/s00592-015-0745-9 (ISSN: 0940-5429).
  • Dapagliflozin versus Sulfonylurea as an add-on therapy to Metformin: a Cost-effectiveness analysis in Costa Rica. Elgart JF, Gonzalez L, Prestes M, Vinocour M, Solorzano J, Gagliardino JJ. ISPOR 21st International Meeting, Washington, USA. Value in Health. 2016; 19(3):A202.
  • Cost-effectiveness of Dapagliflozin in the treatment of type 2 diabetes mellitus in Peru. Elgart JF, Gonzalez L, Prestes M, Manrique H, Solorzano J, Gagliardino JJ. ISPOR 21st International Meeting, Washington, USA. Value in Health. 2016; 19(3):A203.
  • Cost of type 2 diabetes treatment in Latin America: effect of degree of metabolic control. Elgart JF, Gonzalez L, Prestes M, Gagliardino JJ. ISPOR 21st International Meeting, Washington, USA. Value in Health. 2016; 19(3):A201.
  • Dapagliflozin: Cost effectiveness as an add-on therapy to metformin in the treatment of type 2 diabetes in Ecuador. Elgart JF, Prestes M, Gonzalez L, Solis Sanchez C, Acosta W, Solorzano J, Gagliardino JJ. ISPOR 21st International Meeting, Washington, USA. Value in Health. 2016; 19(3):A202.
  • Impacto del grado de control metabólico sobre el costo del tratamiento Farmacológico de la diabetes tipo 2 en Argentina. Elgart JF, González L, Prestes M, Gagliardino JJ. XX Congreso Argentino de Diabetes, Sociedad Argentina de Diabetes (SAD). Revista de la SAD. 2016.
  • Cost-effectiveness of dapagliflozin as an add-on therapy to metformin in the treatment of type 2 diabetes (T2DM) in the Dominican Republic and Guatemala. Elgart JF, Prestes M, Gonzalez L, Solorzano J, Gagliardino JJ. ISPOR 19th Annual Europena Congress. Value in Health, 2016; 19(7):A671–A672.

2015

  • Análisis de Costo-Efectividad de la Educacion de pacientes con Diabetes Tipo 2 por Pares. Gonzalez L, Elgart JF, Prestes M, Gagliardino JJ. ISPOR 5th Latin America Conference, Santiago, Chile. Value in Health. 2015; 18(7):A864-865
  • Impacto Presupuestario de Incorporar Linagliptina para el tratamiento de la Diabetes en Argentina. Elgart JF, Prestes M, Gonzalez L, De los Santos MC, Gagliardino JJ. ISPOR 5th Latin America Conference, Santiago, Chile. Value in Health. 2015; 18(7):A863